Rising Respiratory Problems to drive the Idiopathic Pulmonary Fibrosis Treatment Market Growth

Idiopathic Pulmonary Fibrosis Treatment
Idiopathic Pulmonary Fibrosis Treatment



Idiopathic Pulmonary Fibrosis Treatment Market is segmented by Drug Type (Nintedanib, Pirfenidone, and Other Drug Types), Mode of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, and Other Modes of Action), End User (Hospitals and Clinics and Other End Users), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

According to Coherent Market Insights the Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2022-2028.

Market Overview

Pulmonary fibrosis is a lung disorder that happens while lung tissue becomes impaired and scarred. This clotted, stiff tissue makes it very tough for the lungs to function properly. As pulmonary fibrosis deteriorates, one starts suffering from breathlessness. The lung destruction occurred by pulmonary fibrosis cannot be cured, however drugs and therapeutics can often help decrease symptoms and enhance quality of life.

Competitive Landscape:

Key players involved in the growth of global Idiopathic Pulmonary Fibrosis Treatment Market are Jubilant Cadista, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Afferent Pharmaceuticals, Genentech USA Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Cipla Inc., FibroGen, Prometic Life Sciences,

Market Key Drivers:

The rising prevalence of idiopathic pulmonary fibrosis is expected to augment the growth of the global Idiopathic Pulmonary Fibrosis Market. For instance, as per NIH, around 30,000 to 40,000 people across the globe suffer from idiopathic pulmonary fibrosis.

The rising research and development is anticipated to propel the growth of global Idiopathic Pulmonary Fibrosis Market. For instance, in April 2022, Curebase started the pilot phase of COMPANION, the first medical trial of a new digital therapeutic for individuals with IPF, a rare lung disease.

Covid-19 Impact Analysis:

The Covid-19 outbreak has adversely affected the growth of the global Idiopathic Pulmonary Fibrosis Treatment Market due to the rising respiratory problems Patients with persistent chronic lung diseases, such as idiopathic pulmonary fibrosis, are known to be at high risk of fatality. COVID-19 patients met comorbidities with IPF further rising the necessity for its therapeutics, hence impeding the market growth.

Key Takeaways:

The global Idiopathic Pulmonary Fibrosis Market is expected to exhibit a CAGR of 7.55 % during the forecast period owing to the rising geriatric population. For instance, in October 2021 as per WHO, there would be around 1 billion geriatric people in 2020 and 2.1 billion geriatric people by 2050.

Among regions, North America, Asia Pacific and Europe anticipated to witness robust growth in the global Idiopathic Pulmonary Fibrosis t Market due to rising IPF, increasing respiratory problems, rising partnerships, rising geriatric population, collaborations and acquisitions. For instance, as per Administration of Community Living’s 2020 Profile, in May 2021, in the United States there were around 54.1 million population aged 65 years or above and the number is expected to reach 94.7 million by 2060.

Comments

Popular posts from this blog

Global Flocculant And Coagulant Market Is Estimated To Witness High Growth Owing To Increasing Demand For Water Treatment Applications

Oilfield Chemicals Help Improve the Efficacy and Efficiency of Activities at an Oilfield Site

Global Aniline Market Is Expanding Owing To Growing Adoption of Aniline in Formulating Rubber Processing Chemicals and Increasing Demand for Premium Furnishings and Automotive Interiors